{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:21:44Z","timestamp":1793402504349,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["NIH\/NHLBI R01HL144406"],"award-info":[{"award-number":["NIH\/NHLBI R01HL144406"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implement Sci Commun"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of people living with HIV (PLHIV) and health workers in a routine HIV care setting in Kampala, Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured interviews with 25 PLHIV and 10 health workers at an HIV\/AIDS clinic in Kampala, Uganda. For both groups, we explored their understanding and interpretations of TB and TB preventive therapy (TPT), and perceptions about social and contextual factors that might influence the willingness of PLHIV to initiate and complete 3HP. We analyzed the data using an inductive thematic approach and aligned the emergent themes to the Behavior Change Wheel framework to identify sources of behavior and targeted behavior change interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Facilitators of acceptance and completion of 3HP treatment among PLHIV were fear of contracting TB, awareness of being at risk of getting TB, willingness to take TPT, trust in health workers, and the perceived benefits of directly observed therapy (DOT) and self-administered therapy (SAT) 3HP delivery strategies. Barriers included inadequate understanding of TPT, fear of potential side effects, concerns about the effectiveness of 3HP, and the perceived challenges of DOT or SAT. Among health workers, perceived facilitators included knowledge that TB is a common cause of mortality for PLHIV, fear of getting TB, and trust in the health workers by PLHIV, the advantages of once-weekly 3HP dosing, and the benefits of DOT and SAT 3HP delivery strategies. Health worker-reported barriers for PLHIV included inadequate understanding of TB and benefits of TPT, TB-associated stigma, potential side effects pill burden, and challenges of DOT and SAT 3HP delivery strategies. Lack of experience in the use of digital technology to monitor patient care was identified as a health worker-specific barrier. Identified intervention functions to address the facilitators or barriers included education, persuasion, environmental restructuring, enablement, and training.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using a formative qualitative and comprehensive theoretical approach, we identified key barriers, facilitators, and appropriate interventions, including patient education, enhancing trust, and patient-centered treatment support that could be used to optimize the delivery of 3HP to PLHIV in our setting. These interventions are likely generalizable to other clinical interventions in similar populations in sub-Saharan Africa and other TB high-burden settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43058-021-00173-2","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:02:56Z","timestamp":1625043776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda\u2014patient and health worker perspectives"],"prefix":"10.1186","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-7640","authenticated-orcid":false,"given":"Fred C.","family":"Semitala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Musinguzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Ssemata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Welishe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Nabunje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Katamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kiwanuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses R.","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Katahoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"173_CR1","unstructured":"UNAIDS. Tuberculosis - good progress, but not enough. 2020 [cited 2020 8 May 2020]; Available from: https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2020\/march\/20200323_tb."},{"issue":"11","key":"173_CR2","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","volume":"5","author":"A Badje","year":"2017","unstructured":"Badje A, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080\u20139.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"173_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"Medicine, T.A.S.G.J.N.E.J.o","year":"2015","unstructured":"Medicine, T.A.S.G.J.N.E.J.o. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808\u201322.","journal-title":"N Engl J Med"},{"key":"173_CR4","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"WHO","year":"2018","unstructured":"WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management: World Health Organization; 2018."},{"key":"173_CR5","volume-title":"Guidelines on the management of latent tuberculosis infection","author":"WHO","year":"2015","unstructured":"WHO. Guidelines on the management of latent tuberculosis infection: World Health Organization; 2015."},{"issue":"2","key":"173_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.trstmh.2011.10.015","volume":"106","author":"P Namuwenge","year":"2012","unstructured":"Namuwenge P, et al. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg. 2012;106(2):84\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"173_CR7","volume-title":"Report of a \"lessons learnt\" workshop on the six ProTEST pilot projects in Malawi, South Africa and Zambia","author":"WHO","year":"2004","unstructured":"WHO. Report of a \"lessons learnt\" workshop on the six ProTEST pilot projects in Malawi, South Africa and Zambia: World Health Organization; 2004."},{"issue":"23","key":"173_CR8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"173_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"7","key":"173_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.5588\/ijtld.20.0010","volume":"24","author":"JL Kadota","year":"2020","unstructured":"Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, et al. Willingness to accept reimbursement for visits to an HIV clinic for tuberculosis preventive therapy. Int J Tuberc Lung Dis. 2020;24(7):729\u201331. https:\/\/doi.org\/10.5588\/ijtld.20.0010.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"173_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng PJ, Millet JP, Cayl\u00e0 JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689\u201397. https:\/\/doi.org\/10.7326\/M17-1150.","journal-title":"Ann Intern Med"},{"issue":"1","key":"173_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13033-015-0027-5","volume":"9","author":"E Aakhus","year":"2015","unstructured":"Aakhus E, et al. Tailoring interventions to implement recommendations for the treatment of elderly patients with depression: a qualitative study. Int J Ment Heal Syst. 2015;9(1):36.","journal-title":"Int J Ment Heal Syst"},{"issue":"1","key":"173_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13012-016-0466-7","volume":"11","author":"H Elsey","year":"2015","unstructured":"Elsey H, et al. Understanding implementation and feasibility of tobacco cessation in routine primary care in Nepal: a mixed methods study. Implement Sci. 2015;11(1):104.","journal-title":"Implement Sci"},{"issue":"6","key":"173_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1037\/pro0000153","volume":"48","author":"GM Reger","year":"2017","unstructured":"Reger GM, et al. Barriers and facilitators to mobile application use during PTSD treatment: clinician adoption of PE coach. Prof Psychol Res Pract. 2017;48(6):510.","journal-title":"Prof Psychol Res Pract"},{"key":"173_CR15","volume-title":"Qualitative methods in implementation science","author":"Health, U.D.o. and M","year":"2018","unstructured":"Health, U.D.o. and M. Human services %J National Institutes of Health. In: Qualitative methods in implementation science. Bethesda: National Cancer Institute; 2018."},{"issue":"7262","key":"173_CR16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/bmj.321.7262.694","volume":"321","author":"M Campbell","year":"2000","unstructured":"Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ (Clinical research ed). 2000;321(7262):694\u20136. https:\/\/doi.org\/10.1136\/bmj.321.7262.694.","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"173_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1748-5908-7-37","volume":"7","author":"J Cane","year":"2012","unstructured":"Cane J, O\u2019Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7(1):37. https:\/\/doi.org\/10.1186\/1748-5908-7-37.","journal-title":"Implement Sci"},{"issue":"1","key":"173_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13012-018-0821-y","volume":"13","author":"LK McDonagh","year":"2018","unstructured":"McDonagh LK, et al. Application of the COM-B model to barriers and facilitators to chlamydia testing in general practice for young people and primary care practitioners: a systematic review. Implement Sci. 2018;13(1):130.","journal-title":"Implement Sci"},{"key":"173_CR19","volume-title":"The COM-B theory of change model","author":"Mayne, J.J.u","year":"2018","unstructured":"Mayne, J.J.u. The COM-B theory of change model; 2018. www.researchgate.net\/publication\/314086441_The_COM-B_Theory_of_Change_Model_V3"},{"key":"173_CR20","first-page":"146","volume-title":"The behaviour change wheel: a guide to designing interventions","author":"S Michie","year":"2014","unstructured":"Michie S, Atkins L, West RJNPL. The behaviour change wheel: a guide to designing interventions, vol. 26; 2014. p. 146."},{"issue":"1","key":"173_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, Van Stralen MM, West RJIS. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.","journal-title":"Implement Sci"},{"issue":"1","key":"173_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13012-020-01025-8","volume":"15","author":"JL Kadota","year":"2020","unstructured":"Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, et al. Protocol for the 3HP options trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020;15(1):65. https:\/\/doi.org\/10.1186\/s13012-020-01025-8.","journal-title":"Implement Sci"},{"key":"173_CR23","volume-title":"Qualitative methods for Health Research","author":"J Green","year":"2004","unstructured":"Green J, Thorogood N. Qualitative methods for Health Research: SAGE Publications; 2004."},{"key":"173_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8","volume-title":"Naturalistic inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic inquiry: SAGE; 1985."},{"issue":"7","key":"173_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.5588\/ijtld.20.0010","volume":"24","author":"JL Kadota","year":"2020","unstructured":"Kadota JL, Katamba A, Musinguzi A, Welishe F, Nabunje J, Ssemata JL, et al. Reimbursing visits for tuberculosis preventive therapy among people living with HIV in Uganda: a willingness-to-accept survey. Int J Tuberculosis Lung Dis. 2020;24(7):729\u201331. https:\/\/doi.org\/10.5588\/ijtld.20.0010.","journal-title":"Int J Tuberculosis Lung Dis"},{"issue":"12","key":"173_CR26","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S1473-3099(17)30488-7","volume":"17","author":"C Yoon","year":"2017","unstructured":"Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2017;17(12):1285\u201392. https:\/\/doi.org\/10.1016\/S1473-3099(17)30488-7.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"173_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246113","volume":"16","author":"RK Lim","year":"2021","unstructured":"Lim RK, Semitala FC, Atuhumuza E, Sabiti L, Namakula-Katende J, Muyindike WR, et al. Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. PLoS One. 2021;16(2):e0246113. https:\/\/doi.org\/10.1371\/journal.pone.0246113.","journal-title":"PLoS One"},{"issue":"2","key":"173_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"173_CR29","doi-asserted-by":"publisher","DOI":"10.4135\/9781446280119","volume-title":"Essential guide to qualitative methods in organizational research","author":"C Cassell","year":"2004","unstructured":"Cassell C, Symon G. Essential guide to qualitative methods in organizational research: Sage; 2004."},{"issue":"1","key":"173_CR30","doi-asserted-by":"publisher","first-page":"160940691773384","DOI":"10.1177\/1609406917733847","volume":"16","author":"LS Nowell","year":"2017","unstructured":"Nowell LS, et al. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):1609406917733847.","journal-title":"Int J Qual Methods"},{"issue":"1","key":"173_CR31","first-page":"26","volume":"17","author":"M Mindachew","year":"2014","unstructured":"Mindachew M, et al. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17(1):26.","journal-title":"Pan Afr Med J"},{"issue":"7","key":"173_CR32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/09540121.2017.1283390","volume":"29","author":"KB Jacobson","year":"2017","unstructured":"Jacobson KB, et al. \u201cIt\u2019s about my life\u201d: facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care. 2017;29(7):936\u201342.","journal-title":"AIDS Care"},{"issue":"4","key":"173_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5588\/ijtld.18.0740","volume":"24","author":"H Kim","year":"2020","unstructured":"Kim H, et al. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis. 2020;24(4):396\u2013402.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"173_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/civ766","volume":"62","author":"NL Stennis","year":"2016","unstructured":"Stennis NL, et al. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in new York City health department clinics. Clin Infect Dis. 2016;62(1):53\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"173_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cid\/civ766","volume":"62","author":"NL Stennis","year":"2016","unstructured":"Stennis NL, Burzynski JN, Herbert C, Nilsen D, Macaraig M. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York city health department clinics. Clin Infect Dis. 2016;62(1):53\u20139. https:\/\/doi.org\/10.1093\/cid\/civ766.","journal-title":"Clin Infect Dis"},{"key":"173_CR36","volume-title":"Digital health for the end TB strategy: an agenda for action","author":"WHO","year":"2015","unstructured":"WHO. Digital health for the end TB strategy: an agenda for action: World Health Organization; 2015."},{"issue":"11","key":"173_CR37","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.2196\/jmir.9825","volume":"20","author":"CK Lam","year":"2018","unstructured":"Lam CK, McGinnis Pilote K. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: an implementation study. J Med Internet Res. 2018;20(11):e287.","journal-title":"J Med Internet Res"}],"container-title":["Implementation Science Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-021-00173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43058-021-00173-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-021-00173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:22:07Z","timestamp":1625044927000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationsciencecomms.biomedcentral.com\/articles\/10.1186\/s43058-021-00173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["173"],"URL":"https:\/\/doi.org\/10.1186\/s43058-021-00173-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-92783\/v1","asserted-by":"object"}]},"ISSN":["2662-2211"],"issn-type":[{"value":"2662-2211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"8 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the School of Public Health Higher Degrees Research and Ethics Committee at the Makerere University College of Health Sciences, the Uganda National Council of Science and Technology, and the University of California San Francisco Committee on Human Research. All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}